{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:22:34Z","timestamp":1777029754731,"version":"3.51.4"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.mehy.2019.109288","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T09:50:49Z","timestamp":1561629049000},"page":"109288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Phosphodiesterase 5 inhibitors and adrenal incidentalomas"],"prefix":"10.1016","volume":"130","author":[{"given":"Ioannis","family":"Ilias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Zabuliene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2019.109288_b0005","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.2174\/138161206778343064","article-title":"Expression, distribution and regulation of phosphodiesterase 5","volume":"12","author":"Lin","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2019.109288_b0010","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1161\/ATVBAHA.109.201327","article-title":"A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1\/vascular endothelial growth factor pathway","volume":"30","author":"Sahara","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.mehy.2019.109288_b0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/CCO.0000000000000528","article-title":"Screening in adrenal tumors","volume":"31","author":"Corssmit","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.mehy.2019.109288_b0020","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s12253-017-0259-6","article-title":"Angiogenesis and lymphangiogenesis in the adrenocortical tumors","volume":"24","author":"Pereira","year":"2018","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.mehy.2019.109288_b0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fendo.2016.00111","article-title":"Alterations of phosphodiesterases in adrenocortical tumors","volume":"7","author":"Hannah-Shmouni","year":"2016","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.mehy.2019.109288_b0030","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1210\/jc.2008-0847","article-title":"The type 5 phosphodiesterase inhibitor tadalafil influences salivary cortisol, testosterone, and dehydroepiandrosterone sulphate responses to maximal exercise in healthy men","volume":"93","author":"Di Luigi","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2019.109288_b0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1569-9056(10)60206-0","article-title":"The effect of phosphodiesterase type 5-A inhibitors chronic use on the adrenal glands","volume":"9","author":"Drenidis","year":"2010","journal-title":"Eur Urology Suppl"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719305614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719305614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T14:58:27Z","timestamp":1564757907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987719305614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":7,"alternative-id":["S0306987719305614"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109288","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphodiesterase 5 inhibitors and adrenal incidentalomas","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109288"}}